Matrix metalloproteinase inhibitors as anticancer agents.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International Journal of Biochemistry and Cell Biology

• Publication date

  2008-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.biocel.2007.11.007PMID 18164645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Therapies for the Treatment of Small-Cell Lung Cancer

  2012cited by this paper
• Matrix metalloproteinases.

  2010cited by this paper
• The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo

  2007cited by this paper
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

  2007cited by this paper
• Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

  2007cited by this paper
• Investigational agents for treatment of AIDS-related Kaposi’s sarcoma

  2007cited by this paper
• Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy.

  2007cited by this paper
• Management of AIDS-related Kaposi's sarcoma.

  2007cited by this paper
• BASIC SCIENCE REVIEW

  2006cited by this paper
• Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

  2006cited by this paper
• Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.

  2006cited by this paper
• Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer.

  2006cited by this paper
• Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★

  2006influential reference
• Recent advances in understanding the mechanism of action of bisphosphonates.

  2006cited by this paper
• Tetracyclines: nonantibiotic properties and their clinical implications.

  2006cited by this paper
• Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases.

  2006cited by this paper
• FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

  2006cited by this paper
• Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy

  2006cited by this paper
• A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

  2006influential reference
• Gateways to clinical trials.

  2005cited by this paper
• Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

  2005cited by this paper
• Gateways to clinical trials.

  2005cited by this paper
• Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling.

  2005cited by this paper
• 17-AAG: mechanisms of antitumour activity

  2005cited by this paper
• Angiogenic inhibitors: a new therapeutic strategy in oncology

  2005cited by this paper
• MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

  2005cited by this paper
• Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.

  2005cited by this paper
• Genes that mediate breast cancer metastasis to lung

  2005cited by this paper
• siRNA mediated inhibition of MMP‐1 reduces invasive potential of a human chondrosarcoma cell line

  2005cited by this paper
• The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding

  2005cited by this paper
• A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

  2004cited by this paper
• Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.

  2004cited by this paper
• A Protective Role for Matrix Metalloproteinase-3 in Squamous Cell Carcinoma

  2004cited by this paper
• Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates.

  2004cited by this paper
• The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells.

  2004cited by this paper
• Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.

  2004cited by this paper
• Altered Metastatic Behavior of Human Breast Cancer Cells after Experimental Manipulation of Matrix Metalloproteinase 8 Gene Expression

  2004cited by this paper
• Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.

  2003cited by this paper
• Mechanism of action of bisphosphonates

  2003cited by this paper
• CMT-3. CollaGenex.

  2003cited by this paper
• Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects

  2003cited by this paper
• Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction

  2003cited by this paper
• Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.

  2003cited by this paper
• Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2003cited by this paper
• Loss of collagenase-2 confers increased skin tumor susceptibility to male mice

  2003cited by this paper
• Inhibition of MMP‐1 expression by antisense RNA decreases invasiveness of human chondrosarcoma

  2003cited by this paper
• Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

  2002influential reference
• Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Metalloelastase (MMP‐12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome

  2002cited by this paper
• A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.

  2002cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.

  2002cited by this paper
• Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer.

  2002cited by this paper
• Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

  2002influential reference
• Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

  2002cited by this paper
• Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer

  2002cited by this paper
• BMS-275291. Bristol-Myers Squibb.

  2002cited by this paper
• Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.

  2001cited by this paper
• Pharmacokinetics, Safety, and Tolerability of BAY 12–9566 and Nonsteroidal Anti‐inflammatory Agents (Naproxen, Ibuprofen) during Coadministration in Patients with Osteoarthritis

  2001cited by this paper
• Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

  2001cited by this paper
• Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1*

  2001cited by this paper
• CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer.

  2001cited by this paper
• Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide.

  2001cited by this paper
• Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance

  2001cited by this paper
• Metalloproteinases in biology and pathology of the nervous system

  2001cited by this paper
• A phase II trial of marimastat in advanced pancreatic cancer

  2001influential reference
• Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

  2001cited by this paper
• Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

  2001cited by this paper
• Involvement of chemokine receptors in breast cancer metastasis

  2001cited by this paper
• Development of matrix metalloproteinase inhibitors in cancer therapy.

  2001cited by this paper
• Ongoing trials with matrix metalloproteinase inhibitors

  2000cited by this paper
• Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin.

  2000cited by this paper
• [Matrix metalloproteinase inhibitors].

  2000influential reference
• Matrix metalloproteinases: biologic activity and clinical implications.

  2000cited by this paper
• MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis.

  2000cited by this paper
• Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis.

  2000cited by this paper
• MMP-9 Supplied by Bone Marrow – Derived Cells Contributes to Skin Carcinogenesis

  2000cited by this paper
• Marimastat: the clinical development of a matrix metalloproteinase inhibitor

  2000cited by this paper
• Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

  2000influential reference
• Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas

  1999cited by this paper
• The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.

  1999cited by this paper
• Tissue inhibitors of metalloproteinases (TEMP) in invasion and proliferation

  1999cited by this paper
• Regulation of matrix metalloproteinase expression in tumor invasion

  1999cited by this paper
• Matrix metalloproteinases and metastasis

  1999cited by this paper
• Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

  1999cited by this paper
• Clinical Potential of Matrix Metalloprotease Inhibitors

  1999cited by this paper
• Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.

  1999cited by this paper
• Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.

  1999cited by this paper
• A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window.

  1999cited by this paper
• Matrix metalloproteinases and their inhibitors in tumour growth and invasion.

  1999cited by this paper
• Design and therapeutic application of matrix metalloproteinase inhibitors.

  1999cited by this paper
• Clinical studies with matrix metalloproteinase inhibitors

  1999cited by this paper
• BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity.

  1999cited by this paper
• Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.

  1999cited by this paper
• Role of thymic peptides as transmitters between the neuroendocrine and immune systems.

  1999cited by this paper
• Matrix Metalloproteinases*

  1999cited by this paper
• Marimastat in patients with advanced pancreatic cancer: a dose-finding study.

  1999cited by this paper
• Matrix metalloproteinase‐1 is associated with poor prognosis in oesophageal cancer

  1998cited by this paper
• Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

  1998cited by this paper

• Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance.

  2025cites this paper
• Dual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives

  2022cites this paper
• The Impact of Obesity, Adipose Tissue, and Tumor Microenvironment on Macrophage Polarization and Metastasis

  2022cites this paper
• Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies.

  2020cites this paper
• Cancer Associated Fibroblasts (CAFS) and their Indispensable Role in Tumor Microenvironment: An Update

  2020cites this paper
• Matrix metalloproteinases (MMPs) in targeted drug delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix metalloproteinases-7.

  2020cites this paper
• Fabrication of plumbagin on silver nanoframework for tunable redox modulation: Implications for therapeutic angiogenesis

  2019cites this paper
• The Role of Calcineurin/NFAT Signaling in Fibroblast Homeostasis and Activation

  2019cites this paper
• Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy.

  2018cites this paper
• Role of Extracellular Matrix in Development and Cancer Progression

  2018cites this paper
• Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity.

  2018cites this paper
• Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer

  2018cites this paper
• Mehanizmi djelovanja fenolnih kiselina na oksidacijski stres, polarizaciju makrofaga, angiogenezu i rast Ehrlichova ascitesnoga tumora

  2018cites this paper
• The effect of lipoaspirates vs. dissected abdominal fat on breast cancer cells in vitro

  2017cites this paper
• Evaluation of [18 F]BR420 and [18 F]BR351 as radiotracers for MMP-9 imaging in colorectal cancer.

  2017cites this paper
• Tumor Microenvironment

  2017cites this paper
• Arming Oncolytic Adenoviruses with Transgenes to Engage Stroma Toxicity and Immune Stimulation as a Double Strategy Against Cancer

  2017cites this paper
• Design and synthesis of novel prodrugs to modulate GABA receptors in cancer

  2017cites this paper
• Cancer associated fibroblasts: An essential role in the tumor microenvironment

  2017cites this paper
• Anticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: Activating GSK-3β and degrading β-catenin.

  2016cites this paper
• Design, (radio)synthesis and applications of radiolabelled matrix metalloproteinase inhibitors for PET

  2015cites this paper
• Development and preclinical comparison of two non- peptidomimetic MMP/ADAM inhibitors for PET

  2015influential citation
• Clonal Expansion of T Cells in Abdominal Aortic Aneurysm: A Role for Doxycycline as Drug of Choice?

  2015cites this paper
• Chapter 11 - Other Nonbiological Approaches to Targeted Cancer Chemotherapy

  2015cites this paper
• MicroPET Evaluation of a Hydroxamate-Based MMP Inhibitor, [18F]FB-ML5, in a Mouse Model of Cigarette Smoke-Induced Acute Airway Inflammation

  2015cites this paper
• Compounds leached from quinoa seeds inhibit matrix metalloproteinase activity and intracellular reactive oxygen species

  2015cites this paper
• A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.

  2015cites this paper
• MECHANISMS OF TUMOR PROGRESSION

  2014cites this paper
• The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion

  2014cites this paper
• Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood–brain barrier integrity?

  2014cites this paper
• Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review

  2014cites this paper
• Matrix metalloproteinase 9 opposes diet-induced muscle insulin resistance in mice

  2014cites this paper
• Matrix metalloproteinase enzymes and their naturally derived inhibitors: novel targets in photocarcinoma therapy.

  2014cites this paper
• Pigment epithelium‐derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment

  2014cites this paper
• Activatable FRET Nanosensor for Visualizing MT1-MMP Activity in Single Cancer Cell

  2014cites this paper
• Impact of proteolytic enzymes in colorectal cancer development and progression.

  2014cites this paper
• Blood-Brain Barrier and Cerebral Malaria: The Road So Far

  2014cites this paper
• Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: A mini‐review

  2014cites this paper
• Anti-proliferative and metastatic protease inhibitory activities of protoberberines: An in silico and in vitro approaches

  2013cites this paper
• The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.

  2013cites this paper
• Potential Clinical Applications of Matrix Metalloproteinase Inhibitors and their Future Prospects

  2013cites this paper
• MMP7 and MMP8 genetic polymorphisms in bladder cancer patients

  2013cites this paper
• (-)-Epigallocatechin-3-gallate blocks nicotine-induced matrix metalloproteinase-9 expression and invasiveness via suppression of NF-κB and AP-1 in endothelial cells.

  2013cites this paper
• Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT.

  2013influential citation
• Cepharanthine Suppresses Metastatic Activity of Cholangiocarcinoma Cells

  2013cites this paper
• Investigation of the functions of matrix metalloproteinase-8 (MMP-8) in mammary carcinoma cells

  2013cites this paper
• University of Groningen Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT Matusiak,

  2013influential citation
• Integrins as a potential target for targeted anticancer therapy

  2012cites this paper
• MMP-2 selectivity in hydroxamate-type inhibitors.

  2012cites this paper
• Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment.

  2012cites this paper
• Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes.

  2012cites this paper
• Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.

  2012cites this paper
• The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer

  2012cites this paper
• Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment.

  2012cites this paper
• Selection and Finding of Lead Peptides Dual-targeting MMP14 and Metal Ions by Subtractive Cell Surface Panning and Molecular Docking

  2012cites this paper
• Cepharanthine suppresses metastatic potential of human cholangiocarcinoma cell lines.

  2012cites this paper
• The Role of Inflammation and Proteinases in Tumor Progression

  2012cites this paper
• Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.

  2011cites this paper
• Orally Active, Antimetastatic, Nontoxic Diphenyl Ether‐Derived Carbamoylphosphonate Matrix Metalloproteinase Inhibitors

  2011cites this paper
• Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.

  2011cites this paper
• Regulation of matrix metalloproteinase expression

  2011cites this paper
• Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting

  2011cites this paper
• Molecular pathogenesis of non muscle-invasive bladder cancer: implications for novel targeted therapies.

  2011cites this paper
• MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.

  2011influential citation
• Cancer Associated Fibroblasts as Therapeutic Targets

  2011cites this paper
• Matrix metalloproteinases: fold and function of their catalytic domains.

  2010cites this paper
• The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia.

  2010cites this paper
• Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.

  2010cites this paper
• Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target

  2010cites this paper
• Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).

  2010cites this paper
• Matrix metalloproteinases.

  2010cites this paper
• Wenn das Eiweiß mit dem Zucker …

  2010cites this paper
• PROTEASE INHIBITORS AS ANTICANCER AGENTS

  2010cites this paper
• Recent advances in the development of MMPIs and APNIs based on the pyrrolidine platforms.

  2010cites this paper
• Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways.

  2010cites this paper
• Methanol extract of Elaeagnus glabra, a Korean medicinal plant, inhibits HT1080 tumor cell invasion.

  2009cites this paper
• Pro-invasive role of MMP-9 and c-Met in faslodex-resistant breast cancer

  2009cites this paper
• MMPs in invasion and metastasis, and their use as targets for anti-cancer therapy

  2009cites this paper
• Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC.

  2009cites this paper
• RNAi targeting urokinase‐type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo

  2009cites this paper
• The effect of a hydroxamic acid-containing polymer on active matrix metalloproteinases.

  2009cites this paper
• Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor.

  2009cites this paper
• Multitargeted therapy of cancer by green tea polyphenols.

  2008cites this paper
• Novel therapeutics in metastatic bladder cancer

  2008cites this paper
• Novel therapeutics in metastatic bladder cancer.

  2008cites this paper
• Structural bases for substrate and inhibitor recognition by matrix metalloproteinases.

  2008cites this paper